Overview
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
Description
This study is multi-center, prospective, long-term follow-up observational study.
Eligibility
Inclusion Criteria:
- Age over 19 at the time of obtaining the informed consent form
- Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
- ECOG 0 or 1
- Scheduled to RO or R1 resection
- Organ function capable of chemotherapy
Exclusion Criteria:
- FOLFIRINOX contraindications among the drug approval requirements
- Palliative Therapy
- Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX